The nation of Zimbabwe has turned down a major American health deal worth $367m (£272m) spanning five years over Washington's insistence on sensitive information.
The decision became public after a official document from December was disclosed, revealing that President Emmerson Mnangagwa believed the agreement was "unbalanced".
An official representative has since explained that the United States was seeking genetic material for research and commercial gain but refused to guarantee the benefits from future vaccines.
"We are forced to start the difficult and regrettable task of ending our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had provided over $1.9bn for health programmes to Zimbabwe over the last two decades.
A medical body in Zimbabwe has appealed for more dialogue to find a deal acceptable to both sides so the nation's vital HIV programme can be sustained.
Broader Context
Zimbabwe's decision comes after a comparable situation in Kenya, where a high court suspended a similar health funding agreement following legal challenges were raised about the safety of citizens' health data.
After returning to office recently, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
The agency had managed assistance for the US government, but Trump stated its spending was "wasteful" and his administration was seeking direct bilateral deals to enhance transparency and accountability.
As per reports, Sixteen African countries have to date signed these new agreements, constituting more than $18.3bn of fresh investment.
Details of the Rejected Deal
The funds for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership could have provided significant benefits for the people of Zimbabwe, particularly the 1.2 million presently on HIV treatment through US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Zimbabwe was being asked to provide its biological resources and data over an extended period, with no equivalent guarantee of benefiting from any medical innovations – like new medicines or tests – that might result from that shared data," he stated.
"In essence, our nation would supply the basic resources for scientific discovery without any assurance that the final treatments would be accessible to our population if a new pandemic emerge."
Sovereignty and International Frameworks
He also noted that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were upending structures previously set up via the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to manage potential global health emergencies.
"This system is designed to guarantee that when a country contributes its information, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We are open to further dialogue with our US partners on how subsequent collaboration could be arranged in a way that honours the sovereignty and interests of each country."
Medical Community Reaction
Medical experts said it acknowledged the government's concerns, but suggested that talks must proceed considering a large portion of the country's HIV programmes depended on international support.
"In cases where specific concerns arise, including those relating to data governance or implementation frameworks, these can frequently be resolved through detailed discussion and mutually agreed protections," it said.
The halted deal highlights the complex debate between receiving crucial international aid and safeguarding local interests in an increasingly interconnected world.